Your shopping cart is currently empty

MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM). MKI-1 exerts radiosensitizer and antitumor activities through PP2A activation in breast cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $61 | In Stock | In Stock | |
| 2 mg | $88 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $222 | In Stock | In Stock | |
| 25 mg | $357 | In Stock | In Stock | |
| 50 mg | $490 | In Stock | In Stock | |
| 100 mg | $689 | In Stock | In Stock | |
| 200 mg | $978 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $162 | In Stock | In Stock |
| Description | MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM). MKI-1 exerts radiosensitizer and antitumor activities through PP2A activation in breast cancer. |
| Targets&IC50 | MASTL:9.9 μM |
| In vitro | MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells. MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells. MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells. MKI-1 clearly reduces both total c-Myc and serine 62-phosphorylation of c-Myc, with a decrease in ENSA phosphorylation[1]. |
| In vivo | MKI-1 (50 mg/kg, ip, twice a week) enhances the radiosensitivity of the BT549 xenograft model to 6 Gy irradiation, reducing tumor growth without significant changes in body weight [1]. |
| Synonyms | MASTL Kinase Inhibitor-1 |
| Molecular Weight | 302.33 |
| Formula | C18H14N4O |
| Cas No. | 1190277-80-5 |
| Smiles | O=C(Nc1nc2ccccc2[nH]1)c1cccc(c1)-n1cccc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 225 mg/mL (744.22 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.